June 2009 Volume 9 Number 6
Visit Nature Reviews Cancer online to browse the journal.
Now available at http://links.ealert.nature.com/ctt?kn=16&m=33136454&r=MTc2Njc4NzkyNgS2&b=2&j=NDk5NTM3MDQS1&mt=1&rt=0
Please note that you need to be a subscriber to enjoy full text access
to Nature Reviews Cancer online. To purchase a subscription,
please visit: http://links.ealert.nature.com/ctt?kn=18&m=33136454&r=MTc2Njc4NzkyNgS2&b=2&j=NDk5NTM3MDQS1&mt=1&rt=0
Alternatively, to recommend a subscription to your library, please visit
http://links.ealert.nature.com/ctt?kn=32&m=33136454&r=MTc2Njc4NzkyNgS2&b=2&j=NDk5NTM3MDQS1&mt=1&rt=0
*********************************************************************
Nature Reviews Cancer Impact Factor: 29.19 *
(*Journal Citation Reports, Thomson, 2007)
*********************************************************************
=========================== ADVERTISEMENT ===========================
What if you could wield the full power of next-gen sequencing - affordably?
What if you could study populations large enough to be statistically significant?
Introducing Agilent's SureSelect Target(TM) Enrichment System, a DNA capture
platform for sequencing studies of any size. With SureSelect, you see just the
genomic regions that matter to you. Learn more at
http://links.ealert.nature.com/ctt?kn=47&m=33136454&r=MTc2Njc4NzkyNgS2&b=2&j=NDk5NTM3MDQS1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
IT'S NOW FREE TO POST YOUR VACANCY ON
naturejobs.com
http://links.ealert.nature.com/ctt?kn=86&m=33136454&r=MTc2Njc4NzkyNgS2&b=2&j=NDk5NTM3MDQS1&mt=1&rt=0
It's the breakthrough you've been waiting for. Naturejobs.com - the
scientific jobs board from Nature now lets you advertise your vacancy
completely FREE OF CHARGE
Go to http://links.ealert.nature.com/ctt?kn=15&m=33136454&r=MTc2Njc4NzkyNgS2&b=2&j=NDk5NTM3MDQS1&mt=1&rt=0 or telephone:
Europe: +44 (0) 20 78434961
US: + 1 800 9897718
=========================== ADVERTISEMENT ===========================
FREE ARTICLE
Novel strategies for HIV therapy
http://links.ealert.nature.com/ctt?kn=71&m=33136454&r=MTc2Njc4NzkyNgS2&b=2&j=NDk5NTM3MDQS1&mt=1&rt=0
Two research teams are proposing the use of known compounds-the mild
surfactant glycerol monolaurate and a protein called griffithsin that
could be scaled up in tobacco-be used to block distinct steps in the
early stages of HIV infection. Both teams already have
commercial links but what challenges lay ahead?
Find out more by reading the first in-depth analysis of the scientific and commercial
potential of the work in SciBX: Science-Business eXchange.
http://links.ealert.nature.com/ctt?kn=82&m=33136454&r=MTc2Njc4NzkyNgS2&b=2&j=NDk5NTM3MDQS1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
This month's Featured article:
High-throughput insertional mutagenesis screens in mice to identify
oncogenic networks
Jaap Kool and Anton Berns
p389 | doi:10.1038/nrc2647
http://links.ealert.nature.com/ctt?kn=87&m=33136454&r=MTc2Njc4NzkyNgS2&b=2&j=NDk5NTM3MDQS1&mt=1&rt=0
=====================================================================
From the editors
p379 | doi:10.1038/nrc2673
http://links.ealert.nature.com/ctt?kn=33&m=33136454&r=MTc2Njc4NzkyNgS2&b=2&j=NDk5NTM3MDQS1&mt=1&rt=0
----------------------
RESEARCH HIGHLIGHTS
----------------------
Therapeutics: Selectively targeting turnover
p381 | doi:10.1038/nrc2666
http://links.ealert.nature.com/ctt?kn=40&m=33136454&r=MTc2Njc4NzkyNgS2&b=2&j=NDk5NTM3MDQS1&mt=1&rt=0
Proteomics: Biomarkers on a nanoscale
p382 | doi:10.1038/nrc2659
http://links.ealert.nature.com/ctt?kn=43&m=33136454&r=MTc2Njc4NzkyNgS2&b=2&j=NDk5NTM3MDQS1&mt=1&rt=0
Mouse Models: Closer than you think
p382 | doi:10.1038/nrc2662
http://links.ealert.nature.com/ctt?kn=22&m=33136454&r=MTc2Njc4NzkyNgS2&b=2&j=NDk5NTM3MDQS1&mt=1&rt=0
IN THE NEWS
An ounce of prevention?
p382 | doi:10.1038/nrc2671
http://links.ealert.nature.com/ctt?kn=7&m=33136454&r=MTc2Njc4NzkyNgS2&b=2&j=NDk5NTM3MDQS1&mt=1&rt=0
IN BRIEF
Epigenetics | Metabolism | Biomarkers | Resistance
p383 | doi:10.1038/nrc2670
http://links.ealert.nature.com/ctt?kn=11&m=33136454&r=MTc2Njc4NzkyNgS2&b=2&j=NDk5NTM3MDQS1&mt=1&rt=0
Metastasis: Attack of the mutant p53
p384 | doi:10.1038/nrc2658
http://links.ealert.nature.com/ctt?kn=78&m=33136454&r=MTc2Njc4NzkyNgS2&b=2&j=NDk5NTM3MDQS1&mt=1&rt=0
Tumour Suppressors: Multi-tasking
p384 | doi:10.1038/nrc2660
http://links.ealert.nature.com/ctt?kn=84&m=33136454&r=MTc2Njc4NzkyNgS2&b=2&j=NDk5NTM3MDQS1&mt=1&rt=0
Melanoma: A more accurate diagnosis
p385 | doi:10.1038/nrc2661
http://links.ealert.nature.com/ctt?kn=36&m=33136454&r=MTc2Njc4NzkyNgS2&b=2&j=NDk5NTM3MDQS1&mt=1&rt=0
Prostate cancer: Resistance is (hopefully) futile
p386 | doi:10.1038/nrc2668
http://links.ealert.nature.com/ctt?kn=4&m=33136454&r=MTc2Njc4NzkyNgS2&b=2&j=NDk5NTM3MDQS1&mt=1&rt=0
Therapy: FGFR3 is key
p386 | doi:10.1038/nrc2669
http://links.ealert.nature.com/ctt?kn=50&m=33136454&r=MTc2Njc4NzkyNgS2&b=2&j=NDk5NTM3MDQS1&mt=1&rt=0
TRIAL WATCH
Personalized cocktails | Early warning
p386 | doi:10.1038/nrc2672
http://links.ealert.nature.com/ctt?kn=42&m=33136454&r=MTc2Njc4NzkyNgS2&b=2&j=NDk5NTM3MDQS1&mt=1&rt=0
Genomics: A modular approach to signalling
p387 | doi:10.1038/nrc2667
http://links.ealert.nature.com/ctt?kn=83&m=33136454&r=MTc2Njc4NzkyNgS2&b=2&j=NDk5NTM3MDQS1&mt=1&rt=0
----------------------
REVIEWS
----------------------
High-throughput insertional mutagenesis screens in mice to identify
oncogenic networks
Jaap Kool and Anton Berns
p389 | doi:10.1038/nrc2647
Completion of the mouse genome sequence and improved technologies for
cloning and sequencing of retroviral insertions have allowed researchers
to address new questions about the genes and signalling networks involved
in tumour development.
Abstract: http://links.ealert.nature.com/ctt?kn=87&m=33136454&r=MTc2Njc4NzkyNgS2&b=2&j=NDk5NTM3MDQS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=64&m=33136454&r=MTc2Njc4NzkyNgS2&b=2&j=NDk5NTM3MDQS1&mt=1&rt=0
p21 in cancer: intricate networks and multiple activities
Tarek Abbas and Anindya Dutta
p400 | doi:10.1038/nrc2657
p21 has a well-known role in mediating p53-induced growth arrest. However,
this protein can affect many other cellular functions and is activated
independently of p53. What are the p53-independent roles of p21 in cancer,
and could p21 be a therapeutic target?
Abstract: http://links.ealert.nature.com/ctt?kn=54&m=33136454&r=MTc2Njc4NzkyNgS2&b=2&j=NDk5NTM3MDQS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=77&m=33136454&r=MTc2Njc4NzkyNgS2&b=2&j=NDk5NTM3MDQS1&mt=1&rt=0
The biology of ovarian cancer: new opportunities for translation
Robert C. Bast, Jr, Bryan Hennessy and Gordon B. Mills
p415 | doi:10.1038/nrc2644
Ovarian cancer is a heterogeneous disease, making it difficult to provide
standard regimens that are effective for all patients. Can increases in
long-term survival be achieved by translating recent insights at the
molecular and cellular levels into individual strategies for treatment
and optimal early detection?
Abstract: http://links.ealert.nature.com/ctt?kn=41&m=33136454&r=MTc2Njc4NzkyNgS2&b=2&j=NDk5NTM3MDQS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=20&m=33136454&r=MTc2Njc4NzkyNgS2&b=2&j=NDk5NTM3MDQS1&mt=1&rt=0
Cancer prevention by tea: animal studies, molecular mechanisms and
human relevance
Chung S. Yang, Xin Wang, Gang Lu and Sonia C. Picinich
p429 | doi:10.1038/nrc2641
Extracts of tea, especially green tea, and tea polyphenols have been
shown to inhibit the formation and development of tumours at different
organ sites in animal models. How well are these data holding up in
humans and what are the biological mechanisms of action?
Abstract: http://links.ealert.nature.com/ctt?kn=5&m=33136454&r=MTc2Njc4NzkyNgS2&b=2&j=NDk5NTM3MDQS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=93&m=33136454&r=MTc2Njc4NzkyNgS2&b=2&j=NDk5NTM3MDQS1&mt=1&rt=0
----------------------
PERSPECTIVES
----------------------
OPINION
Article series: MYC
http://links.ealert.nature.com/ctt?kn=79&m=33136454&r=MTc2Njc4NzkyNgS2&b=2&j=NDk5NTM3MDQS1&mt=1&rt=0
Facilitating replication under stress: an oncogenic function of MYC?
Steffi Herold, Barbara Herkert and Martin Eilers
p441 | doi:10.1038/nrc2640
Recent publications have indicated that the proto-oncogene MYC is
closely involved in DNA replication and S phase checkpoint processes,
and have suggested that limiting replication stress is a key function
of this protein. How do these findings affect our understanding of how
MYC transforms cells?
Abstract: http://links.ealert.nature.com/ctt?kn=10&m=33136454&r=MTc2Njc4NzkyNgS2&b=2&j=NDk5NTM3MDQS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=55&m=33136454&r=MTc2Njc4NzkyNgS2&b=2&j=NDk5NTM3MDQS1&mt=1&rt=0
OPINION
Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we
see the wood for the trees?
Stefan Lob, Alfred Konigsrainer, Hans-Georg Rammensee, Gerhard Opelz and Peter Terness
p445 | doi:10.1038/nrc2639
Indoleamine-2,3-dioxygenase (IDO) is an immunosuppressive enzyme that
is expressed in tumours and enables them to escape immunologically mediated
rejection. However, we are far from understanding the biological relevance
of IDO expression during tumorigenesis. We need a better understanding of
IDO biology to provide a rationale for the use of IDO inhibitors in the clinic.
Abstract: http://links.ealert.nature.com/ctt?kn=35&m=33136454&r=MTc2Njc4NzkyNgS2&b=2&j=NDk5NTM3MDQS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=30&m=33136454&r=MTc2Njc4NzkyNgS2&b=2&j=NDk5NTM3MDQS1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
Informative, stimulating and compelling coverage of the hottest topics in science.
Nature News offers you a spotlight on scientific news events around the world.
For daily news, extensive features, columns, in-depth focuses and interactive specials:
Access http://links.ealert.nature.com/ctt?kn=51&m=33136454&r=MTc2Njc4NzkyNgS2&b=2&j=NDk5NTM3MDQS1&mt=1&rt=0
=====================================================================
You have been sent this Table of Contents Alert because you have opted in to
receive it. You can change or discontinue your e-mail alerts at any time,
by modifying your preferences on your nature.com account at:
http://links.ealert.nature.com/ctt?kn=12&m=33136454&r=MTc2Njc4NzkyNgS2&b=2&j=NDk5NTM3MDQS1&mt=1&rt=0
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact our customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York |
NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston
(c) Copyright 2009 Nature Publishing Group
=====================================================================
